Guardant Health (GH) Research & Development (2017 - 2026)

Guardant Health (GH) has 10 years of Research & Development data on file, last reported at $91.0 million in Q1 2026.

• Quarterly Research & Development rose 2.84% year-over-year to $91.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $366.7 million (up 4.04% YoY) and the FY2025 annual result came in at $364.2 million, up 4.73% from the prior year.
• Research & Development retreated to $91.0 million in Q1 2026 per GH's latest filing, from $98.3 million in the prior quarter.
• The five-year high for Research & Development was $106.6 million in Q4 2022, with the low at $81.8 million in Q1 2022.
• Average Research & Development over 5 years is $90.8 million, with a median of $90.0 million recorded in 2025.
• Year-over-year, Research & Development surged 47.29% in 2022 and slipped 15.69% in 2023.
• Guardant Health's Research & Development stood at $106.6 million in 2022, then declined by 15.69% to $89.9 million in 2023, then gained by 4.1% to $93.5 million in 2024, then climbed by 5.05% to $98.3 million in 2025, then slipped by 7.35% to $91.0 million in 2026.
• Business Quant data shows GH's Research & Development at $91.0 million in Q1 2026, $98.3 million in Q4 2025, and $90.0 million in Q3 2025.